Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.

The structure–activity relationship of a series of tricyclic-sulfonamide compounds 11–32 culminating in the discovery of N-[trans-4-(4,5-dihydro-3,6-dithia-1-aza-benzo[e]azulen-2-ylamino)-cyclohexylmethyl]-methanesulfonamide (15, Lu AA33810) is reported. Compound 15 was identified as a selective and high affinity NPY5 antagonist with good oral bioavailability in mice (42%) and rats (92%). Dose dependent inhibition of feeding was observed after i.c.v. injection of the selective NPY5 agonist ([cPP1–7,NPY19–23,Ala31,Aib32,Gln34]-hPP). In addition, ip administration of Lu AA33810 (10mg/kg) produced antidepressant-like effects in a rat model of chronic mild stress.